Delta-1: a global, multicenter, phase 2 study of Itil-168, an unrestricted autologous tumorinfiltrating lymphocyte (Til) cell therapy, in adult patients with advanced cutaneous melanoma
Gastman, B. Sarnaik, A. Lawrence, D. Olszanski, A. Chmielowski, B. Lutzky, J. Butler, M. Hamid, O. Corrie, P. Domingo-Musibay, E.
Gastman, B.
Sarnaik, A.
Lawrence, D.
Olszanski, A.
Chmielowski, B.
Lutzky, J.
Butler, M.
Hamid, O.
Corrie, P.
Domingo-Musibay, E.
Citations
Altmetric:
Abstract
Authors
Gastman, B.
Sarnaik, A.
Lawrence, D.
Olszanski, A.
Chmielowski, B.
Lutzky, J.
Butler, M.
Hamid, O.
Corrie, P.
Domingo-Musibay, E.
Thomas, S.
Thistlethwaite, Fiona C
Daniels, G.
Evans, T.
Furness, A.
Gibney, G.
Harries, M.
Medina, T.
Olson, D.
Pallan, L.
Whitman, E.
Wilson, M.
Aycock, J.
Hawkins, R.
Jiang, Y. Z.
Kennedy, A.
Robbins, P.
Roberts, Z.
Le Gall, J.
Sarnaik, A.
Lawrence, D.
Olszanski, A.
Chmielowski, B.
Lutzky, J.
Butler, M.
Hamid, O.
Corrie, P.
Domingo-Musibay, E.
Thomas, S.
Thistlethwaite, Fiona C
Daniels, G.
Evans, T.
Furness, A.
Gibney, G.
Harries, M.
Medina, T.
Olson, D.
Pallan, L.
Whitman, E.
Wilson, M.
Aycock, J.
Hawkins, R.
Jiang, Y. Z.
Kennedy, A.
Robbins, P.
Roberts, Z.
Le Gall, J.
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Gastman B, Sarnaik A, Lawrence D, Olszanski A, Chmielowski B, Lutzky J, et al. Delta-1: A Global, Multicenter, Phase 2 Study of Itil-168, an Unrestricted Autologous Tumorinfiltrating Lymphocyte (Til) Cell Therapy, in Adult Patients with Advanced Cutaneous Melanoma. Journal for immunotherapy of cancer. 2022 Nov;10:A819-A. PubMed PMID: WOS:000919423400743.